Telephonic CBT Versus Face-to-Face CBT for Depression

Michele Reed, PharmD
Published Online: Wednesday, October 10, 2012
Follow Pharmacy_Times:
A randomized, controlled trial of primary care patients with major depressive disorder (n=325) evaluated the effect of telephone-administered cognitive behavioral therapy (T-CBT) compared with face-to-face CBT in the treatment of depression.1 Study subjects were randomized to receive 18 sessions of T-CBT or face-to-face CBT. The primary end point of the study was attrition (completion vs noncompletion) at post-treatment (week 18).

The study demonstrated that both treatments significantly improved patient depression (P <.001). Additionally, significantly fewer participants discontinued T-CBT (n = 34; 20.9%) compared with face-to-face CBT (n = 53; 32.7%; P = .02).

Results also showed that participants receiving face-to-face CBT were significantly less depressed than those receiving T-CBT on the Ham-D (difference, 2.91; 95% CI, 1.20-4.63; P <.001) and the PHQ-9 (difference, 2.12; 95% CI, 0.68-3.56; P = .004).

The investigators concluded that T-CBT improves adherence com- pared with face-to-face delivery; however, the benefit of treatment may diminish after treatment cessation.

Dr. Reed received her doctor of pharmacy degree from the University of the Sciences in Philadelphia, Pennsylvania, and currently works as a medical editor in the greater Philadelphia area.

1. Mohr DC, Ho J, Duffecy J, et al. Effect of telephone-administered vs face-to-face cognitive behavioral therapy on adherence to therapy and depression outcomes among primary care patients: a randomized trial. JAMA. 2012;307(21):2278-2285.

Related Articles
A 20 mg dose of vilazodone HCl (Viibryd) is now available in pharmacies to treat adult patients with major depressive disorder.
Reduced sleep duration is linked to more repetitive negative thinking.
Pfizer’s serotonin and norepinephrine reuptake inhibitor, desvenlafaxine (Pristiq), has low potential for causing sexual dysfunction in patients with major depressive disorder.
A first-of-its-kind blood test delivers an objective diagnosis of major depressive disorder, as well as predicts which adult patients will benefit from cognitive behavioral therapy.
Latest Issues